Waltz Health Launches Revolutionary Model for Obesity Treatment
This innovative approach combines transparency, clinical integrity, and support to enable employers to meet the growing demand for FDA-approved obesity medications.
Recently announcing its direct-to-employer (DTE) access model for FDA-approved obesity management medicines, Waltz Health, an EVERSANA company, is set to transform how self-insured employers provide coverage for these vital treatments. This pioneering program focuses on delivering comprehensive solutions that include clinical safeguards, clear pricing structures, and extensive employee support. By launching directly to employers and through consulting channels, this model serves as a crucial component in modern employee benefit strategies.
Set to launch on January 1, 2026, the model will offer fixed pricing alongside an integrated support ecosystem that complements each employer's existing benefits. Waltz Health aims to simplify the entire process for employees by providing real-time eligibility checks, efficient pharmacy routing, prescription adjudication, and continuous engagement tools for better patient experience and adherence monitoring.
The Chief Executive Officer of Waltz Health, Mark Thierer, stated, "Obesity management medicines are redefining care expectations, and employers are in search of solutions that promote clinical responsibility while being financially sustainable." He added that this model is designed to provide employers with structure and visibility in order to enhance employee experience and coverage.
Employees can access their necessary treatments through their current healthcare providers or via a telehealth option woven throughout the program. Waltz Health ensures that all procedures meet FDA requirements, directs prescriptions to pharmacies with reliable inventory, and features ongoing digital resources for tracking refills and adherence.
Recent research highlights that employee expectations for access to obesity medications have skyrocketed. Many employees are open to changing jobs for better coverage, which emphasizes the urgent need for employer-sponsored solutions that align with their evolving benefit priorities. Unfortunately, while a little over half of corporate health plans provide coverage for obesity medications for employees with diabetes, only around one in five currently support weight management treatments.
This new model addresses existing market challenges that have made traditional access methods cumbersome. By fostering a direct-to-employer framework, it effectively removes barriers, offering consistent pricing, adherence monitoring, and real-time clinical reviews that ease the path for employers and their employees.
Notably, Novo Nordisk is on board with this model, aiming to provide more affordable weight loss medications while ensuring a superior experience for patients.
Ed Cinca, Senior Vice President of Marketing and Patient Solutions at Novo Nordisk, noted, "We aim for individuals requiring weight management to have easier access to treatment while ensuring they receive authentic FDA-approved medications. Our collaboration across the healthcare landscape advocates for a streamlined patient experience, which prioritizes health and facilitates better long-term results for patients."
This innovative initiative enables employers to offer their employees access to groundbreaking treatments without compromising on financial viability or clinical oversight. The model promises a transparent, accountable, and scalable solution, allowing employers to provide benefits reflecting the latest advancements in clinical care while retaining control over cost and quality.
In addition, Waltz Health is partnering with Eli Lilly and Company to enhance access to its obesity management solutions.
Kevin Hern, Senior Vice President at Lilly USA, remarked, “Employers express the need to support employee health but frequently encounter challenges in securing coverage for obesity management medicines. We are eager to collaborate with organizations that share our passion for reducing complexity and facilitating employers in extending access to essential treatments.”
As the demand for obesity medications and other high-value therapies escalates, Waltz Health's model sets the stage for a more responsive and responsible future in employer-sponsored healthcare.
About Waltz Health
Waltz Health is a pioneering digital health company focused on improving decision-making related to prescription care. Their innovative offerings aim to assist payers, pharmacies, benefit managers, and self-insured employers by leveraging AI-driven marketplaces to lower drug costs and offer consumers better pricing alternatives coupled with comprehensive insights. Founded in 2021 by Mark Thierer and Jonathon Thierer, Waltz Health operates out of Chicago and is supported by various prominent investors. For further information, please visit their official website.
Frequently Asked Questions
What is the new model introduced by Waltz Health?
The new direct-to-employer model for obesity management medicines allows self-insured employers to provide coverage with transparent pricing and clinical safeguards.
When will the new model be launched?
The model is set to launch on January 1, 2026, integrating fixed pricing and support to streamline the employee experience.
How does Waltz Health support employees in managing obesity?
Waltz Health offers access through healthcare providers or telehealth and provides digital support tools for tracking and adherence.
What is the significance of this model for employers?
The model allows employers to offer innovative obesity management treatments without sacrificing financial sustainability, ensuring clinical oversight.
Who are the partners involved in this initiative?
Novo Nordisk and Eli Lilly are collaborating with Waltz Health to provide access to affordable obesity management medications.
